TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
89bio ( (ETNB) ) has issued an update.
On October 30, 2025, 89bio concluded a merger process, resulting in the termination of its Loan and Security Agreement from January 2023. The merger led to the company becoming a wholly owned subsidiary of the Parent company, with significant changes in the company’s stock and management structure, including the delisting of its shares from Nasdaq and the resignation of its board members.
The most recent analyst rating on (ETNB) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on 89bio stock, see the ETNB Stock Forecast page.
Spark’s Take on ETNB Stock
According to Spark, TipRanks’ AI Analyst, ETNB is a Neutral.
The overall score for 89bio is primarily weighed down by the financial performance due to ongoing losses and cash flow issues. Technical indicators show bearish momentum, adding to the risk. Although corporate events highlight promising clinical progress, the company’s valuation remains low due to negative earnings, typical in the biotech industry. The stock reflects high-risk, high-reward potential.
To see Spark’s full report on ETNB stock, click here.
More about 89bio
Average Trading Volume: 5,392,262
Technical Sentiment Signal: Buy
Current Market Cap: $2.2B
Find detailed analytics on ETNB stock on TipRanks’ Stock Analysis page.